MENLO PARK, Calif., March. 30,
2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a
specialty pharmaceutical company, will share early preclinical
research that suggests potent anti-proliferative and apoptotic
effects of molecular iodine on two types of breast cancer cell
lines.
Findings will be shared via a poster entitled "Elucidating the
Mechanism of Action of Molecular Iodine on Breast Cancer Cells,"
which will be presented at the American Association for Cancer
Research Annual Meeting, from 1 p.m. to 5
p.m. Monday, in Washington.
BioPharmX researchers analyzed the impact of molecular iodine on
gene expression and antiproliferative changes in the luminal A
breast cancer derived cell line (MCF-7), the triple negative breast
cancer cell line (MDA-MB231) and primary human mammary epithelial
cells from a healthy donor. They found expressions of nuclear
hormone receptors PPARs and RXR were up-regulated and BCL-2 and
Caspase 3, both regulators of cell death, were increased. This
suggests that molecular iodine can specifically inhibit cellullar
proliferation and drive cell death in certain breast cancer cell
lines without apparent toxicity to normal breast cells.
"The possibility that a known, non-toxic, and
non-chemotherapeutic molecule may have a differential regulating
effect on breast cancer cells versus normal breast cells is very
exciting," said Lee P. Shulman,
Professor of Ob/Gyn at the Feinberg School of Medicine of
Northwestern University in Chicago, Illinois. "The
results indicate that iodine inhibits the in vitro
proliferation of MCF-7 and MDA-MB231 breast cancer cells."
The researchers' gene expression analysis using qRT-PCR also
confirmed that key cell cycle genes responsible for controlling
G1-S phase transition were significantly up-regulated.
The findings of our in vitro research studies demonstrate
that molecular iodine exhibits antiproliferative and apoptotic
effects in mammary cancer cell lines and further elucidates
molecular iodine's cellular mechanism of action in these breast
cancer cells.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company that seeks to provide products through proprietary platform
technologies for prescription, over-the-counter and supplement
applications in dermatology and women's health. To learn more about
BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statement
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions and strategies,
including, but not limited to, statements regarding potential
outcomes of its research programs, whether molecular iodine can
successfully targets certain types of breast cancer cells, and
whether molecular iodine will have anti-proliferative effects.
These forward-looking statements may be identified by words such as
"plan", "expect," "anticipate," "believe," or similar expressions
that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties,
as well as assumptions, which, if they do not fully materialize or
prove incorrect, could cause our results to differ materially from
those expressed or implied by such forward-looking statements. The
risks and uncertainties include those described in the company's
filings with the Securities and Exchange Commission. Given these
risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-aacr-poster-will-present-findings-suggesting-molecular-iodine-inhibits-breast-cancer-cell-growth-and-drives-cancer-cell-death-300431663.html
SOURCE BioPharmX Corporation